A novel anti-CD3xCD28xSTEAP1 trispecific T-cell engager (HLX3902) with enhanced and durable antitumor responses in prostate cancer

Background

Immunotherapy has demonstrated limited efficacy in prostate cancer, largely due to the immunosuppressive tumor microenvironment, poor T-cell